John R. Cashman, Ph.D.
John R. Cashman, Ph.D., Chief Executive Officer, has more than 30 years experience in biomedical research as a researcher, consultant, entrepreneur or administrator. In 1997, he founded the Human BioMolecular Research Institute, a non-profit research institute dedicated to conducting fundamental and applied research to address important human diseases of the central nervous system. Previously, he was Senior Scientist at the Seattle Biomedical Research Institute and prior to that, he was Associate Director for the IGEN Research Institute in Seattle, Washington. In 1984, he was appointed Assistant Professor of Chemistry and Pharmaceutical Chemistry at the University of California, San Francisco. He completed a postdoctoral fellowship in the Department of Chemistry at Harvard University in Cambridge, Massachusetts with Professor E.J. Corey (1982-1984). In 1990, Professor Corey received the Nobel Prize. Dr. Cashman received his Masters and doctorate degrees in Medicinal Chemistry from the University of Kansas, Lawrence, Kansas (1982). Prior to graduate school, he obtained bachelor degrees in chemistry and biology at the College of Creative Studies, University of California, Santa Barbara (1977). Dr. Cashman was a University of California Presidents Undergraduate Researcher (1974-1976), received a Sigma Xi Undergraduate Research fellowship (1975), was a PEW Scholar Nominee at the University of California, San Francisco (1986), received a March of Dimes Basil O’Connor Research Award (1986), was appointed Technical Advisor, San Francisco Estuary Project (1990) and was elected Fellow of the American Association for the Advancement of Science in 1996. In 1991, Dr. Cashman was appointed to the Editorial Advisory Board, Chemical Research in Toxicology and in 1999 he was appointed to the Editorial Advisory Board of Current Drug Metabolism. Dr. Cashman is the author of over 220 research articles or book chapters and 16 patents in the area of drug discovery and evaluation. He is extensively consulted by biotechnology, pharmaceutical industry and government in various areas of human drug development, drug safety evaluation, medicinal chemistry, pharmacogenetics and biochemical toxicology. Dr. Cashman is on the Board of Directors of four corporations.
Mark Mercola, Ph.D.
Mark Mercola, Ph.D., President earned his Ph.D. from the University of California, Los Angeles in 1985. Dr. Mercola trained as a postdoctoral fellow at the Dana-Farber Cancer Institute and Department of Microbiology at Harvard Medical School in Boston, MA. He was appointed Assistant Professor in the Department of Cell Biology at Harvard Medical School in 1991 and Associate Professor in 1996. Dr. Mercola joined Sanford-Burnham Medical Research Institute in 2002 where he is Professor and Director of the Muscle Development and Regeneration Program, and is also adjunct Professor in the Department of Pathology and the Department of Pediatrics at the University of California, San Diego. In 2007 Dr. Mercola was appointed Associate Director, Neurosciences, Aging and Stem Cell Research Center of the Sanford-Burnham Medical Research Institute. He has extensive experience in small molecule screening as part of his service work for the Conrad Prebys Center for Chemical Genomics and its mission of providing chemical biology and functional genomics services to academic investigators. He established and directs assay development and screening units within the Center, and continues as faculty partner of these units and directs SBMRI core facilities for High Throughput Library Screening and Flow Cytometry.
Dr. Mercola is the President of ChemRegen, Inc. and is internationally recognized for defining the tissue interactions and signaling molecules that control stem cell differentiation. Recently, he has turned his attention to an intriguing signaling pathway that apparently has significant impact on stem cell differentiation and cancer. He is committed to continuing to develop the technology in ChemRegen, Inc., including the biological and biochemical assays relevant to the development of small molecules that target signaling proteins involved in stem cell differentiation and cancer for the development of stem cell differentiation agents and anti-cancer drugs, respectively. Relevant to this project,
Jack Gavin, CFO
John (Jack) Gavin, Chief Financial Officer graduated from the US Naval Academy in June 1977 as a commissioned officer and served with distinction as a Marine Corps officer and Naval Aviator for 20 years.
In August 1998 he received his Masters of Business Administration from San Diego State University. As a Financial Advisor for both Merrill Lynch and Citigroup Global Markets, Jack specialized in Cash Management and Corporate Executive services for life sciences, technology, and manufacturing oriented companies in the Pacific Southwest region. He developed and implemented sophisticated quantitative methods and proprietary reporting systems to manage fixed income portfolios for public and private entities. In February 2007, he assumed his current position, as the Aviation Operations Analyst for Marine Corps battle simulation programs at Marine Air Ground Combat Center, 29 Palms, California. Since 1997, Mr. Gavin has served as ChemRegen’s Chief Financial Officer. In his capacity as Chief Financial Officer, he is primarily responsible for managing the financial risks of the corporation. He is also responsible for financial planning and record-keeping, as well as financial reporting to higher management. Mr. Gavin has controllership duties responsible for presenting and reporting accurate and timely historical financial information of the company. He also has treasury duties and is responsible for the company's present financial condition, investments of the company's money, and oversees the capital structure of the company.
Michael Sherman, Administrator
Michael Sherman, Administrator since 2018.
Mr. Sherman is responsible for the daily operation of ChemRegen. He handles the day-to-day activities that make the company run smoothly. Mr. Sherman handles quality control, personnel issues, worker policies and many other tasks. He meets frequently with other executives of ChemRegen to assess the overall condition of the company with the goal of ensuring that production runs as smoothly as possible.